ArticleMolecular cancer2025
CircZFAND6 suppresses gastric cancer metastasis and reduces resistance to TKI therapy.
Article in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The m6A-circRNA axis: a therapeutic prospect for gastric cancer.Cell biology and toxicology · 2026Review
- Interpretable machine learning-based survival prediction and key gene identification in cancer using gene expression and clinical data.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPeritoneal metastasis, the most common mode of dissemination in gastric cancer (GC), is characterized by resistance to treatment and a poor prognosis. Accumulating evidence indicates that circular RNAs (circRNAs) play a significant role in tumor progression. However, the role of circRNAs in GC peritoneal dissemination (GCPD) remains unknown.
methodsCircRNA profiles in four clinical GCPD specimens were established using RNA-seq. Circular integrity was validated through Sanger sequencing, agarose gel electrophoresis, and RNase R resistance. The expression of Circ_0000643 (circZFAND6) in GC cells was determined by qRT-PCR. Functional assays, both in vitro and in vivo, assessed the suppressive effect of circZFAND6 in GC. Mechanistic studies that included AGO2-RIP, FISH, and luciferase reporter systems identified miR-6815-3p as a direct target of circZFAND6. RNA-seq and Western blotting were utilized to examine the impact of circZFAND6 on the Wnt/β-catenin signaling pathway. The construction of a FLAG-tagged circZFAND6 overexpression plasmid was performed to verify the coding potential of circZFAND6, while murine tumor models were employed to evaluate the synergy between circZFAND6 overexpression and gefitinib. The interaction between the circZFAND6 encoding protein and ERBB3 was demonstrated using co-IP.
resultsCircZFAND6 showed significant downregulation in GC tissues and cell lines, with its reduced expression independently linked to poor prognosis in GC patients. Functional analysis indicated that overexpression of circZFAND6 markedly inhibited GC cell proliferation, migration, and invasion in vitro, while also decreasing peritoneal dissemination in a xenograft mouse model. Mechanistically, circZFAND6 acted as a competitive endogenous RNA (ceRNA) that sponged miR-6815-3p, thus alleviating its post-transcriptional repression of APC mRNA. This resulted in decreased Wnt/β-catenin signaling activity. Our study revealed that circZFAND6 engaged in “rolling translation” to produce the circZFAND6-aa protein, which specifically interacts with ERBB3, thereby hindering EGFR tyrosine kinase activity and downstream AKT signaling pathways to overcome gefitinib resistance in GC.
conclusionsOur study shows that circZFAND6 acts as a tumor suppressor in gastric cancer by regulating the miR-6815-3p/APC/Wnt-β-catenin pathway. Additionally, its novel peptide helps reverse resistance to gefitinib. These findings highlight circZFAND6 as a promising prognostic marker and a potential therapeutic target for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.